Find a Trial

Trial Results


19 protocol(s) meet the specified criteria
0810010067/J591OPEN TO ACCRUAL
A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) with Ketoconazole in Patients with High Risk Castrate Biochemically Relapsed Prostate Cancer after Local Therapy
516-003OPEN TO ACCRUAL
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma
C16-168OPEN TO ACCRUAL
A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects
C16-174OPEN TO ACCRUAL
DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
CTO-20180101OPEN TO ACCRUAL
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-life Extended Bispecific T-cell Engager AMG 160 in Subjects With Metastatic Castration-resistant Prostate Cancer
CTO-A031704OPEN TO ACCRUAL
PD-INHIBITOR (NIVOLUMAB) AND IPILIMUMAB FOLLOWED BY NIVOLUMAB VS. VEGF TKI CABOZANTINIB WITH NIVOLUMAB: A PHASE III TRIAL IN METASTATIC UNTREATED RENAL CELL CANCER [PDIGREE]
CTO-D3618C00002OPEN TO ACCRUAL
A Phase I, Open-label, Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination with Novel Agents in Patients with Metastatic Castration Resistant Prostate Cancer
CTO-E7766-G000-102OPEN TO ACCRUAL
INtravesical Phase 1/1b study of STING Agonist E7766 in NMIBC including subjects Unresponsive to BCG Therapy, INPUT-102
CTO-MK-3475-866OPEN TO ACCRUAL
A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-866)
CTO-MK-3475-905OPEN TO ACCRUAL
A Phase 3 Randomized Study of Cystectomy plus Perioperative Pembrolizumab versus Cystectomy Alone in Cisplatin-ineligible Participants with Muscleinvasive Bladder Cancer (KEYNOTE-905)
CTO-QBGJ398-302OPEN TO ACCRUAL
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF 302)
EA8143OPEN TO ACCRUAL
A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
EA8153OPEN TO ACCRUAL
Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial
GU17-295OPEN TO ACCRUAL
A Phase II Trial of Atezolizumab plus Chemotherapy after Progression on Single Agent PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma
IUSCC-0579OPEN TO ACCRUAL
Salvage High Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors: Indiana University Experience 1990-2015
IUSCC-0584OPEN TO ACCRUAL
COLLECTION OF SPECIMENS AND CLINICAL DATA TO CREATE A BIOREPOSITORY FOR THE GENITOURINARY ONCOLOGY PROGRAM
IUSCC-0611OPEN TO ACCRUAL
Retrospective Analysis of Patients with Metastatic Germ Cell Tumor at Indiana University
IUSCC-0688OPEN TO ACCRUAL
A Retrospective Tissue Analysis of NQO1 Status in Patients with Germ Cell Tumors
IUSCC-0708OPEN TO ACCRUAL
Genomic Analysis of Relapsed/Refractory Germ-Cell Tumors